Working with Ex Vivo Organ Perfusion to reduce inflammation
*Not available in the US
The ECOS-300CY® sorbent cartridge is the first and only product specifically CE approved to remove cytokines and other inflammatory mediators during Ex Vivo Organ Perfusion (EVOP) – one of the newest innovations in solid organ transplant that perfuses harvested organs like the heart, lungs, liver, and kidneys with oxygenated, temperature controlled perfusate or blood.
Proven inflammatory mediator removal and organ preservation efficacy
Interleukin-6
Tumor necrosis factor alpha
Versatile application in a variety of organs and platforms
The new ECOS-300CY Therapy system is the first and only specifically E.U. approved product for cytokine removal in organ perfusion.
ECOS-300CY is a high flow, low resistance technology that easily integrates into the perfusate flow of an EVOP circuit. The purpose of the therapy is to reduce circulating harmful inflammatory toxins during ex vivo organ perfusion to help preserve healthy organs and/or to restore the functioning of marginal ones so that they can be used for transplant.
Viable organs for transplant are scarce and the number of patients awaiting transplant continues to grow globally, with more than 150,000 candidates awaiting transplant in Europe alone. In 2019, 41,000 patients received solid organ transplants in the EU, while 48,000 new patients were added to the transplant list and approximately 4% (or 6,000) died waiting for a transplant.
Organ preservation and reconditioning using EVOP with ECOS-300CY is a promising means of increasing organ availability and improving the success of organ transplantation. Recently published data on the use of our technology with ex vivo lung perfusion and other solid organs like the kidneys to improve organ function and post-transplant outcomes, support the synergy of the two technologies.
The ECOS-300CY cartridge is now available in the European Union, and also under the brand name PerSorb®, sold in conjunction with the PerLife® perfusion platform by our partner Aferetica.
-
ECOS-300CY is a high flow, low resistance technology that easily integrates into the perfusate flow of an EVOP circuit. The purpose of the therapy is to reduce circulating harmful inflammatory toxins during ex vivo organ perfusion to help preserve healthy organs and/or to restore the functioning of marginal ones so that they can be used for transplant.
-
Viable organs for transplant are scarce and the number of patients awaiting transplant continues to grow globally, with more than 150,000 candidates awaiting transplant in Europe alone. In 2019, 41,000 patients received solid organ transplants in the EU, while 48,000 new patients were added to the transplant list and approximately 4% (or 6,000) died waiting for a transplant.
-
Organ preservation and reconditioning using EVOP with ECOS-300CY is a promising means of increasing organ availability and improving the success of organ transplantation. Recently published data on the use of our technology with ex vivo lung perfusion and other solid organs like the kidneys to improve organ function and post-transplant outcomes, support the synergy of the two technologies.
-
The ECOS-300CY cartridge is now available in the European Union, and also under the brand name PerSorb®, sold in conjunction with the PerLife® perfusion platform by our partner Aferetica.
Additional Information
- Hosgood SA et al., J Transl Med. 2017; 15(1):216
- Iskender I et al., JTCVS. 2021; 161(2):e109-e121
- Lindstedt S et al., J Heart Lung Transplant. 2023; 42(10):1358-1362
- Boffini M et al., Transplant Int. 2023; 36:10777
- Niromand A et al., Front Cardiovasc Med. 2023; 10:127444
Contact us to learn more about ECOS – 300CY Therapy
Get in touch
Voices around the world
